TNXP I think the target will be 2.2$TNXP is uptrend above MOV50
RSI > 40
MACD will cross
CMF > 0
I think the target will be 2.2
TPM trade ideas
$TNXP Short Term Profit PossibleRSI shows oversold signal, with a bullish crossover. Uptrend is supported by all the MAs with no entanglement. Shooting STAR is present after a series of red candles. Cup and handle forming on the chart. Suggested buy point reflected on the chart as well. Chart was laid also with blue line for entry, green line for TPs and red for cutloss. Quick bucks possible on this one!
TNXP Harmonics: Target PracticeAfter gaining a sweet entry at the turn, I'll be shooting fish in a barrel with this bat harmonic. Check it out and load or reload around here!
TNXP Harmonics: Re-entry FishingBe aware that there may a different turning point here! We usually stick with it until the turn, so we can capitalize when it does turn. Check it out and load up!
TNXP Harmonics: Target PracticeShooting fish in a barrel over here with these bullish-butterfly take-profit targets. Check it out and load up!
Who is ready for fireworkInstitutions added ✅
Insider bought more shares ✅
Bullish chart set up ✅
All we need now is a news to start the trigger.
Short term target 4$+
Long term 8$+
TNXP: Bullish Pennant, confirmedBullish Pennant, confirmed.
Pros:
Descending volume during formation
Volume increase at break out
Golden cross in blue
PPS above 50MA and 200MA
RS above 0, but descending
ATR Ascending
R/R ratio above 4
200MA ascending
Cons:
250RSI below 50
PT = 2.65$
***TNXP BULLISH***TNXP
Opened a position (1.60$)
Expect it to follow the uptrend
Short term target (2,15$)
Risk: Tight stop loss
I'll close half position at target because of more upside potential.
( You can also put S/L higher )
AFTER NEW RUN, IT MIGHT CORRECT TO THESE LEVELS.
THIS GIVES US AN EXTRA BUY OPPORTUNITY FOR THE LONG RUN
DISCLAIMER:
NOT FINANCIAL ADVICE. MY OPINION/IDEA
$TNXPTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 and TNX-2600, which are live replicating attenuated vaccine candidates for the prevention of COVID-19. In addition, the company's lead CNS candidate is TNX-102 SL, a sublingual formulation of cyclobenzaprine, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR for depression; and TNX-1900 for migraine and cranio-facial pain treatment. Additionally, its preclinical pipeline includes TNX-1600 for posttraumatic stress disorder, depression, and attention deficit hyperactivity disorder; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500 for transplant organ rejection and autoimmune conditions; and TNX-1700 for gastric and pancreatic cancers. The company is headquartered in Chatham, New Jersey.
TNXP short termBased on technical analysis and recent news about the company we can see a push towards 3$ in the short term.
i like it to $1.70 short term i think we can see more outa this i like it to $1.70 holding overnight for continuation
Tonix Pharmaceuticals LONGTERM FORECAST Weekly chart outlook for the long term. I see some upside in the near future . Lets see how this plays out. Mainly publishing to come back and study the price action.
Cup and Handle, ready to pop?Seeing cup and handle in the 1h chart.
Many catalyst brewing.
Going to pop soon, imo.
TNXPTNXP : look at JAGX and the TNXP pattern ... something should immediately come to your mind ....... It is a BOWL or a very similar construction that foresees an explosion of values ... if we then add that their CEO he personally purchased another 35,000 pieces for a total of 118655 pieces at an average price of 0.8 .... SOMETHING IS BOILING IN THE POT ..
$ TNXP Lederman Seth
Bought 35,000 shares × $ 0.68 = $ 23,800
Share count: 118,655 shares (+ 41.84%)
TNXP Potential playSolid bottom forming on this little dude with steady volume rising and running up.
Looks like it wants to test $1.00 and $1.70, With some news it could really go.
Strong support at $0.50-0.60 area
There are working with a Covid Vaccine currently which seems a little late to the game but could yield some hype.
Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL*** (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects topline data in the Phase 3 RALLY study in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-1800**, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.
Could TNXP see %1000 in the near future????Had a great day today with ONTX up 100% just as planned last night. I cant help but feel this stock is going to make millionaires. The CEO bought a large amount of shares this week and just an hour ago the company announced that it will be presenting at 4 bio med conferences. The company has many promising vaccines and treatments in the pipeline such as covid 19 vaccine and fibromyalgia treatment. If the participation in these conferences has to do with positive results from their projects it could be enough of a catalyst to send the price way up. Technical analysis points to huge gains of most likely %300 but there's a slight chance in the future that it could pass this up to ~$6 and from there fill the gap up to $9. The short term technical is definitely a buy. The company has very good potential
